Statera Biopharma (STAB) Stock Price, News & Analysis

Company Overview

Statera Biopharma, Inc. (NASDAQ:STAB) is a clinical-stage biopharmaceutical company dedicated to developing microbiome-based therapies for orphan and rare diseases. The company’s proprietary platform assembles highly characterized bacterial consortia designed to restore gut microbiome balance and modulate systemic immune and neurological pathways. Statera’s lead programs include SB-101, a treatment in clinical development for short bowel syndrome, and SB-121, an investigational therapy entering Phase 2 trials for core symptoms of autism spectrum disorder.

Founded in 2019 and headquartered in Minneapolis, Minnesota, Statera Biopharma completed its public listing through a business combination in early 2021. The company collaborates with academic and clinical research centers to design and execute robust clinical trials, while establishing scalable manufacturing processes to ensure consistency and reproducibility of its bacterial formulations. Its research efforts also encompass exploratory studies in recurrent Clostridium difficile infection and neurodegenerative conditions such as amyotrophic lateral sclerosis.

Under the leadership of President and Chief Executive Officer David Koos, Statera Biopharma continues to advance its pipeline through rigorous regulatory engagement and strategic partnerships. By combining precision microbiome science with a focus on underserved patient populations, the company aims to deliver innovative, first-in-class therapies that address significant unmet medical needs.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 30,538 shs
• Market Capitalization: $5 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

STAB Stock Analysis - Frequently Asked Questions

How do I buy shares of Statera Biopharma?

Shares of STAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Statera Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Statera Biopharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Today: 10/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:STAB
• CIK: 1318641
• Web: www.staterabiopharma.com
• Phone: (888) 613-8802
• Fax: 716-849-6820
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 53,300,000
• Free Float: N/A
• Market Cap: $5 thousand
• Optionable: Not Optionable
• Beta: 0.17